Latest News and Press Releases

Oncolytics Biotech announced that the USPTO has issued a new patent broadly protecting the proprietary manufacturing process for pelareorep into 2044.

Oncolytics Biotech announced the appointment of Steve Glover to its Board of Directors and the promotion of John McAdory to Chief Operating Officer.

Oncolytics announced data demonstrating evidence of greater anti-tumor activity with pelareorep in combination with RAS inhibitor modalities.

Translational data demonstrate induction of both innate and adaptive antiviral and anti-tumor specific immune responses capable of controlling tumor growth

Oncolytics announced new data in metastatic colorectal cancer, demonstrating 3-4x improvement in duration response vs. historical 4-6 month benchmark.

Oncolytics Biotech announced Type C meeting with the FDA aligning on the design of clinical study to support approval of pelareorep in patients with SCAC.

SAN DIEGO, April 06, 2026 (GLOBE NEWSWIRE) -- Oncolytics Biotech® Inc. (Nasdaq: ONCY) (“Oncolytics” or the “Company”), a clinical-stage immunotherapy company developing pelareorep, an...

SAN DIEGO, April 01, 2026 (GLOBE NEWSWIRE) -- Oncolytics Biotech® Inc. (Nasdaq: ONCY) (“Oncolytics” or the “Company”), a clinical-stage immunotherapy company developing pelareorep, today announced...

Pelareorep treatment drives coordinated immune activation and tertiary lymphoid structure formation  Translational data suggest potential to boost response to immunotherapy and targeted therapy in...

Controlled study designed to confirm previous compelling efficacy with preliminary data expected by the end of 2026 Pelareorep-based treatment regimen recently granted Fast Track Designation in 2L...